FIELD: medicine.
SUBSTANCE: invention relates to medicine. Proposed is an EGFR inhibitor for treatment of non-small cell lung cancer caused by mutated NRAS, where the EGFR inhibitor is administered in combination with a MEK inhibitor and an NRAS mutation is selected from E63K, G12V and G12R, or a gain of copy number of NRAS gene.
EFFECT: invention provides effective treatment for non-small cell lung cancer caused by mutated NRAS using a combination of an EGFR inhibitor with an MEK inhibitor.
6 cl, 10 dwg, 7 tbl, 4 ex
| Title |
Year |
Author |
Number |
| METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION |
2016 |
|
RU2736045C2 |
| PEPTIDE VACCINE COMPRISING RAS PEPTIDE CONTAINING MUTATIONS, AND CHEMOTHERAPEUTIC AGENT |
2015 |
- Eriksen, Jon Amund
- Gaudernack, Gustav
|
RU2700929C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR |
2017 |
- Caponigro, Giordano
- Meyer, Matthew John
- Cooke, Vesselina
- Stuart, Darrin
|
RU2774612C2 |
| DETERMINATION OF CELL SENSITIVITY TO TREATMENT WITH B-Raf INHIBITOR BY DETECTION OF K-ras MUTATION AND LEVELS OF RTK EXPRESSION |
2010 |
- Khatzivassiliu Dzhordzhija
- Malek Shiva
|
RU2553379C2 |
| COMBINATION THERAPY |
2018 |
|
RU2815400C2 |
| THERAPEUTIC COMPOSITION FOR REDUCING RESISTANCE TO TYROSINE KINASE INHIBITORS |
2016 |
- D'Hondt, Erik
- Molina Vila, Miguel, Angel
|
RU2735493C2 |
| METHODS AND COMBINED THERAPEUTIC PRODUCT FOR THE TREATMENT OF BILE DUCTS CANCER |
2019 |
|
RU2793543C2 |
| USE OF THIOCHROMENO[2,3-C]QUINOLINE-12-ONE COMPOUND FOR TREATING NON-SMALL CELLS LUNG CANCER |
2016 |
|
RU2663929C2 |
| METHODS FOR TREATING PANCREATIC CANCER |
2017 |
- Bekker Petrus
- Miao Shichang
- Charo Israel
- Schall Tom
|
RU2768479C2 |
| COMPOUNDS CONTAINING MUTANT KRAS SEQUENCE AND LIPIDS AND THEIR USE |
2019 |
- Demuth, Peter, C.
- Adams, Julian
- Steinbuck, Martin
|
RU2809161C2 |
